To maximize the clinical and market opportunities...
...offered by Topica’s unique global business model, the company has assembled a highly experienced scientific, clinical and business team with a proven track record in licensing, product development, regulatory approval and commercialization success. Collectively, this management team has more than 70 years of experience in the biotechnology and pharmaceutical industries, including leadership roles in 14 New Drug and Biologic Licensing Application approvals, 5 of which were through the FDA’s division that is evaluating luliconazole.

Topica’s Management Team

Greg Vontz, President & CEO
22 years of biotechnology and pharmaceutical industry experience
Merck, Genentech, and Connetics

Norifumi Nakamura, Ph.D., Senior VP Corporate Development
8 years academic positions; 19 years in biotechnology and pharmaceuticals
Osaka City Medical School, Harvard Medical School, Green Cross, Anges MG

Joseph Golemme, CFO
20 years of senior financial management experience at CFO level
Price Waterhouse, 3 successful venture-backed companies

Katy Morton, VP Regulatory & Quality Affairs
26 years of regulatory experience and management
Syntex, Alza, Connetics

Mark Davis, VP Clinical Development
28 years of biotechnology, pharmaceutical and medical device experience
Onyx Pharmaceuticals, Connetics and Amgen

Topica’s Board of Directors

Kirk Raab – Chairman, Board of Directors
Former President Abbott Laboratories, CEO of Genentech, Chairman of the board Connetics Corporation and BiPar Sciences

Richard Anthony, Ph.D.,
CEO, Catalyst Pharma Group Inc.

Alex Barkas, PhD
Managing Director, Prospect Venture Partners; founding CEO, Connetics Corporation

Dave Markland
CFO Prospect Venture Partners

Nori Nakamura, PhD
Senior Vice President Corporate Development Topica Pharmaceuticals

Greg Vontz
President and CEO Topica Pharmaceuticals

Topica’s Scientific Advisory Board
Furthermore, the Topica Scientific Advisory Board provides the company with deep and invaluable support on all aspects of development, including the design and conduct of clinical trials, evaluation of current treatment algorithms and trends, assessment of the competitive environment, interaction with the FDA, and the identification of additional development opportunities both now and post-approval. Topica’s SAB members are leading experts in the fields of dermatology and management of onychomycosis.

Jay E. Birnbaum, PhD
Cofounder and former Chief Medical Officer of Kythera Biopharmaceuticals, former Vice President, Global Project Management, at Novartis/Sandoz where he led the development of oral    Lamisil to approval in onychomycosis 

David E. Cohen, MD, MPH
Vice Chairman of Clinical Affairs and Associate Professor of Dermatology at the New York University School of Medicine, Chief of the Allergy Unit/Occupational and Environmental Dermatology at New York University Hospital.

Howard Maibach, MD
University of California, San Francisco School of Medicine, Department of Dermatology, developed state-of-the art technology and methods for measuring nail penetration of dermatology products for treatment of onychomycosis.

Phoebe Rich, MD
Oregon Dermatology & Research Center

Richard Scher, MD, MS
Professor of Dermatology University of North Carolina at Chapel Hill